Teresa Bitetti/LinkedIn
Dec 4, 2024, 18:03
Teresa Bitetti: Addressing treatment gaps across a range of cancers with Keros Therapeutics
Teresa Bitetti, President of Global Oncology at Takeda, shared a post LinkedIn:
“With patient needs at the forefront, we are committed to forming collaborations that can help address treatment gaps across a range of cancers.
Today, I am pleased to share that we have entered into an agreement with Keros Therapeutics to acquire an exclusive license for a promising activin inhibitor currently in development for the treatment of anemia associated with certain Blood Cancers, including Myelodysplastic Syndromes (MDS) and Myelofibrosis (MF).
A heartfelt thank you to all colleagues whose efforts made this deal possible.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 4, 2024, 18:01
Dec 4, 2024, 17:57
Dec 4, 2024, 17:52
Dec 4, 2024, 17:49
Dec 4, 2024, 17:40
Dec 4, 2024, 17:26